Company / SG&A per Share
Monopar Therapeutics SG&A per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$1.11
FY2025
5-year range
$0.13 / $1.11
FY2021-FY2025
Trend
+2.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $0.23 to $1.11 over the past 2 years.
Based on SEC 10-K filings.
1.11 in FY2025.
Increased from $0.23 to $1.11 over the past 2 years.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, sg&a per share increased 2.8% year-over-year.
- Lowest sg&a per share in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 19.82 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.11 | +2.8% |
| FY2024 | $1.08 | +376.5% |
| FY2023 | $0.23 | -10.3% |
| FY2019 | $0.25 | +102.0% |
| FY2018 | $0.13 | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026